세계의 동물용 백신 시장 예측(2025-2030년)

The veterinary vaccines market is expected to grow from USD9.354 billion in 2025 to USD13.758 billion in 2030, at a CAGR of 8.02%.

The veterinary vaccines market is projected to experience significant growth from 2025 to 2030, driven by the rising prevalence of zoonotic diseases, increasing global pet adoption, and growing demand for livestock products. Veterinary vaccines, including live attenuated, inactivated, recombinant, and other types, are critical for preventing disease transmission in companion and agricultural animals, protecting both animal and human health. Administered primarily through parenteral methods, these vaccines are essential in the veterinary healthcare industry. The market is supported by government initiatives and a shift toward preventive healthcare, though stringent regulations may pose challenges.

Market Drivers

Rising Zoonotic Diseases

The increasing incidence of zoonotic diseases is a primary driver of the veterinary vaccines market. Animals can transmit pathogens such as bacteria, viruses, parasites, and fungi, which cause serious illnesses in humans, ranging from mild to fatal. The global burden of zoonotic diseases underscores the need for effective veterinary vaccines to prevent transmission from animals to humans. Government initiatives, such as programs targeting animal virus outbreaks, further boost market growth by promoting vaccination as a key preventive measure. These efforts are particularly critical in regions with high livestock and pet populations, where zoonotic risks are elevated.

Growing Demand in India

The Indian veterinary vaccines market is experiencing steady growth, driven by rising demand for livestock products like meat and dairy, fueled by population growth and changing dietary habits. The poultry and dairy sectors, major contributors to India's agricultural economy, are increasingly adopting vaccines to prevent infectious diseases and ensure healthy animal populations. Farmers' growing awareness of the economic benefits of vaccination, coupled with government programs like the National Animal Disease Control Programme, supports market expansion. High-demand vaccines include those for Peste des petits ruminants (PPR), Brucella, and Foot and Mouth Disease (FMD), reflecting the focus on livestock health.

Increasing Pet Adoption

Global pet adoption rates are rising, particularly for companion animals like dogs and cats, driving demand for veterinary vaccines. This trend is accompanied by increased pet care expenditures, as owners prioritize preventive healthcare to protect their pets and reduce zoonotic risks. The growing popularity of cats, in particular, is contributing to market growth, as pet owners seek vaccines to ensure animal health and safety.

Market Restraints

The veterinary vaccines market faces challenges due to stringent regulatory policies governing vaccine approvals, which can delay market entry and increase development costs. These regulations, while ensuring safety and efficacy, may limit innovation and accessibility, particularly for smaller manufacturers. Additionally, the high cost of advanced vaccines can restrict adoption in price-sensitive markets, such as developing regions, where affordability is a key concern. Addressing these challenges through streamlined regulatory processes and cost-effective vaccine development will be critical for sustained market growth.

Market Segmentation

By Product Type

The market includes live attenuated, inactivated, recombinant, and other vaccines. Parenteral administration dominates due to its effectiveness in delivering targeted immunity. Recombinant vaccines are gaining traction for their precision and safety in addressing specific pathogens.

By Animal Type

The market serves companion animals (e.g., dogs, cats) and agricultural animals (e.g., cattle, poultry). The companion animal segment is growing rapidly due to rising pet ownership, while the agricultural segment remains significant, driven by the need to maintain livestock health and productivity.

By Geography

The market is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. North America leads due to high pet care spending and advanced veterinary infrastructure. Asia-Pacific, particularly India, is expected to grow steadily, driven by increasing livestock production and government support. Europe, South America, and the Middle East and Africa are also poised for growth, supported by rising awareness and improving veterinary services.

The veterinary vaccines market is set for robust growth from 2025 to 2030, driven by rising zoonotic disease risks, growing pet adoption, and increasing demand for livestock products, particularly in India. Despite challenges from stringent regulations and high costs, the market's outlook remains positive, with strong growth in North America and Asia-Pacific. Industry players must focus on innovative, cost-effective vaccines and regulatory compliance to capitalize on the growing demand for preventive animal healthcare solutions.

Key Benefits of this Report:

• Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
• Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
• Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
• Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
• Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

• Historical data from 2020 to 2024 & forecast data from 2025 to 2030
• Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
• Competitive Positioning, Strategies, and Market Share Analysis
• Revenue Growth and Forecast Assessment of segments and regions including countries
• Company Profiling (Strategies, Products, Financial Information, and Key Developments among others.

Segmentation:

By Vaccine Type

• Live, Attenuated Vaccines
• Inactivated/Killed Vaccines
• Toxoid Vaccines
• Subunit & Conjugate Vaccines
• Others

By Mode of Administration

• Oral
• Parental
• Others

By Animal

• Companion Animals
• Livestock Animals
• Cattle
• Poultry
• Swine
• Others

By Geography

• North America
• USA
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• Germany
• UK
• France
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Others
• Asia Pacific
• Japan
• China
• India
• Thailand
• Taiwan
• Indonesia
• Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

• 2.1. Market Overview
• 2.2. Market Definition
• 2.3. Scope of the Study
• 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Porter's Five Forces Analysis
• 3.5. Industry Value Chain Analysis
• 3.6. Policies and Regulations
• 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. VETERINARY VACCINE MARKET BY VACCINE TYPE

• 5.1. Introduction
• 5.2. Live Attenuated Vaccine
• 5.3. Inactive/Killed Vaccine
• 5.4. Toxoid Vaccine
• 5.5. Subunit & Conjugate Vaccine
• 5.6. Others

6. VETERINARY VACCINE MARKET BY MODE OF ADMINISTRATION

• 6.1. Introduction
• 6.2. Oral
• 6.3. Parental
• 6.4. Others

7. VETERINARY VACCINE MARKET BY ANIMAL TYPE

• 7.1. Introduction
• 7.2. Companion Animals
• 7.3. Livestock Animals
  • 7.3.1. Cattle
  • 7.3.2. Poultry
  • 7.3.3. Swine
  • 7.3.4. Others

8. VETERINARY VACCINE MARKET BY GEOGRAPHY

• 8.1. Introduction
• 8.2. North America
  • 8.2.1. By Vaccine Type
  • 8.2.2. By Mode of Administration
  • 8.2.3. By Animal Type
  • 8.2.4. By Country
    • 8.2.4.1. USA
    • 8.2.4.2. Canada
    • 8.2.4.3. Mexico
• 8.3. South America
  • 8.3.1. By Vaccine Type
  • 8.3.2. By Mode of Administration
  • 8.3.3. By Animal Type
  • 8.3.4. By Country
    • 8.3.4.1. Brazil
    • 8.3.4.2. Argentina
    • 8.3.4.3. Others
• 8.4. Europe
  • 8.4.1. By Vaccine Type
  • 8.4.2. By Mode of Administration
  • 8.4.3. By Animal Type
  • 8.4.4. By Country
    • 8.4.4.1. Germany
    • 8.4.4.2. France
    • 8.4.4.3. United Kingdom
    • 8.4.4.4. Spain
    • 8.4.4.5. Others
• 8.5. Middle East and Africa
  • 8.5.1. By Vaccine Type
  • 8.5.2. By Mode of Administration
  • 8.5.3. By Animal Type
  • 8.5.4. By Country
    • 8.5.4.1. Saudi Arabia
    • 8.5.4.2. UAE
    • 8.5.4.3. Israel
    • 8.5.4.4. Others
• 8.6. Asia Pacific
  • 8.6.1. By Vaccine Type
  • 8.6.2. By Mode of Administration
  • 8.6.3. By Animal Type
  • 8.6.4. By Country
    • 8.6.4.1. China
    • 8.6.4.2. India
    • 8.6.4.3. Japan
    • 8.6.4.4. South Korea
    • 8.6.4.5. Indonesia
    • 8.6.4.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

• 9.1. Major Players and Strategy Analysis
• 9.2. Market Share Analysis
• 9.3. Mergers, Acquisitions, Agreements, and Collaborations
• 9.4. Competitive Dashboard

10. COMPANY PROFILES

• 10.1. Elanco
• 10.2. Zoetis Inc.
• 10.3. Ceva
• 10.4. Merck Animal Health
• 10.5. Phibro Animal Health Corporation
• 10.6. Virbac
• 10.7. Hester Bioscience Limited
• 10.8. Hipra
• 10.9. Boehringer Ingelheim International GmbH
• 10.10. AdvaCare Pharma

11. APPENDIX

• 11.1. Currency
• 11.2. Assumptions
• 11.3. Base and Forecast Years Timeline
• 11.4. Key Benefits for the Stakeholders
• 11.5. Research Methodology
• 11.6. Abbreviations